Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Compared to the control group, the vitamin D group was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events (MACE) [risk ratio=0.99; 95% CI: 0.94 to 1.03].

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Effect of vitamin D supplementation on cardiovascular outcomes: an updated meta-analysis of RCTs

Source: Article title.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Effect of vitamin D supplementation on cardiovascular outcomes: an updated meta-analysis of RCTs

Review / evidence synthesis · Annals of Medicine and Surgery · 2024

Original publication title

Effect of vitamin D supplementation on cardiovascular outcomes: an updated meta-analysis of RCTs

Agha M.W. Mirza; Naiela E. Almansouri; Muhammad F. Muslim; Thahaseen Basheer; Sree V. Uppalapati; Swati Lakra; Hareem Fatima; Arshiya Adhnon; Ivo W. Filho; Ruqeyya Mahmood; Mahendra Kumar; Kamal Kandel; Muhammad Ayyan

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0 · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

According to our meta-analysis, vitamin D supplementation did not reduce major adverse cardiovascular events, other cardiovascular parameters, and all-cause mortality. Therefore, vitamin D should not be recommended for the prevention of cardiovascular disease.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate the effect of vitamin D supplementation on cardiovascular outcomes.

Source: Objective:

Study methods

What methods does the paper describe?

Our meta-analysis was conducted according to the guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions and followed the reporting guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA, Supplemental Digital Content 1, http://links.lww.com/MS9/A581) statement21,22. Our study did not require any ethical approval. This meta-analysis has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). This review has been reported in line with the AMSTAR criteria (Supplemental Digital Content 2, http://links.lww.com/MS9/A582).

Eligibility criteria

The inclusion criteria were as follows: (1) only RCTs; (2) adults who received vitamin D in various forms and doses, with or without concurrent calcium administration; (3) studies with at least one cardiovascular outcome reported; (4) studies on only long-term supplementation (≥1-year intervention) of vitamin D. Studies that did not include cardiovascular outcomes or with an intervention period <1 year were excluded. We also excluded observational studies and review studies.

Information sources

We searched electronic databases, gray literature sources, and international trial registries from their inception until September 1, 2023, without imposing any language restrictions. The databases and registries searched included the Cochrane Central Register of Controlled Trials (accessed via the Cochrane Library), MEDLINE (via PubMed), Embase (via Ovid), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform portal. The reference lists of the included studies and relevant meta-analyses were also screened to find other RCTs. A search strategy consisting of a combination of keywords and MeSH terms like vitamin D, ergocalciferol, cholecalciferol, cardiac, myocardial, and cardiovascular were used.

Study selection and data extraction

The retrieved articles from the search were imported into Mendeley Desktop 1.19.8, and any duplicate articles were removed. Two review authors then conducted a two-step process to screen studies: first, by assessing titles and abstracts, and secondly, by reviewing the full-text versions of selected studies. Any disagreements during this process were resolved through discussion, with a plan in place for a third review author to serve as an arbitrator if needed. A PRISMA flow chart was used to visually present the selection process.

Following the completion of the study selection, two reviewers extracted relevant data from selected studies using a standardized data extraction form. This information encompassed various aspects, including study details (such as design, location, year of publication, and author), participant characteristics (including number of participants, age range, and gender distribution), intervention specifics (dosage, duration, and follow-up period), baseline parameters, comparator, and outcome measures assessed.

Outcome measures

The primary outcome is the incidence of major adverse cardiovascular events (MACE). The secondary outcomes included: (1) all-cause mortality, (2) incidence of cardiovascular death, (3) incidence of MI, (4) incidence of cerebrovascular events, (5) incidence of HF, and (6) incidence of coronary revascularization.

Risk of bias assessment

We assessed the risk of bias in the included studies using the revised Cochrane “Risk of bias” tool for randomized trials (RoB 2.0), which assesses bias in five domains: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in the measurement of the outcome, and (5) bias in the selection of the reported result23. Two authors independently assessed the risk of bias in each study that was included, categorizing it as either low-risk, high-risk or have some concerns.

In cases where there were discrepancies between the assessments of the two original authors, a third reviewer was consulted to help make a final decision.

Data synthesis

For each trial, we reported dichotomous outcomes as relative risk (RR) along with 95% confidence intervals. The meta-analysis was conducted when at least two studies reported the relevant outcome data. We used the DerSimonian and Laird random-effects model in our meta-analyses. For detection and quantification of heterogeneity, we calculated the χ 2 test and I 2 statistic. We interpreted I 2 values according to the Cochrane Handbook for Systematic Reviews of Interventions section 10.10. P value <0.10 was considered statistically significant for the χ 2 test24.

All statistical analyses were performed using Review Manager (RevMan, Version 5.4; The Cochrane Collection, Copenhagen, Denmark). The study characteristics and findings of the included studies were presented in the form of tables.

Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods

Results: Incidence of MACE

A total of 10 RCTs reported the incidence of major adverse cardiovascular events (MACE). According to our pooled data, the vitamin D intervention was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events, with the risk ratio being 0.99 (95% CI: 0.94 to 1.03). The heterogeneity between studies was found to be low (I 2=8%) for this outcome (Fig. 2).

Figure 2

Comparison of incidence of MACE between patients receiving vitamin D or control. IV, inverse variance. MACE, major adverse cardiovascular events.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Incidence of MACE Source: Incidence of MACE

Results: All-cause mortality

The all-cause mortality was reported by 15 RCTs in our meta-analysis. We found no difference in the all-cause mortality between the two groups in our meta-analysis [RR 0.96; 95% CI: 0.92 to 1.00]. The heterogeneity between studies was found to be low (I 2=0%) (Fig. 3).

Figure 3

Comparison of all-cause mortality between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: All-cause mortality Source: All-cause mortality

Results: Cardiovascular death

A total of 10 RCTs reported the outcome of cardiovascular death. Vitamin D intervention was not associated with a statistically significant decrease in cardiovascular death [RR 0.99; 95% CI: 0.91 to 1.07]. The heterogeneity between studies was found to be low (I 2=0%) for this outcome (Fig. 4).

Figure 4

Comparison of incidence of cardiovascular death between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Cardiovascular death Source: Cardiovascular death

Results: Incidence of MI

The incidence of MI was reported by 14 RCTs in our meta-analysis. We found no difference in the incidence of MI between the two groups in our meta-analysis [RR 0.97; 95% CI: 0.90 to 1.04]. The heterogeneity between studies was found to be low (I 2=0%) (Supplementary Fig. S1.1, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Source: Incidence of MI

Results: Incidence of cerebrovascular accident

According to our meta-analysis of 12 studies reporting this outcome, vitamin D did not reduce the incidence of cerebrovascular accidents [RR 1.04; 95% CI: 0.97 to 1.12; I 2=0%] (Supplementary Fig. S1.2, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Source: Incidence of cerebrovascular accident

Discussion

According to our meta-analysis of 18 RCTs on 108 385 patients, vitamin D was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events (MACE), all-cause mortality, cardiovascular death, incidence of heart failure, myocardial infarction, cerebrovascular accident, and coronary revascularization. It is noteworthy to note that the evidence was not sufficient on the outcomes of cerebrovascular accident and coronary revascularization rates. Some previous observational studies5,6 showed a potential effect in reducing adverse cardiovascular events but no such association has been observed in many RCTs and previous meta-analyses18,19 conducted on vitamin D effect on cardiovascular outcomes.

Our meta-analysis includes data from a very large randomized controlled trial, the D-Health trial20, which was not included in the previous meta-analyses.

Our meta-analysis’ findings are similar to the results of the previous meta-analyses. Barbarawi et al. 18 reported that vitamin D did not significantly reduce major adverse cardiovascular events [RR 1.00; 95% CI: 0.95 to 1.06]. The effect on myocardial infarction, stroke, CVD mortality, and all-cause mortality was also insignificant. Pei et al. 19 conducted a meta-analysis on 18 RCTs, and they showed a similar effect on all cardiovascular outcomes, including MACE, myocardial infarction, heart failure, and cerebrovascular events. Our meta-analysis is different from the previous meta-analyses in two ways: (1) in this study, we have only included RCTs on long-term (≥1-year intervention) vitamin D supplementation; (2) inclusion of a large trial, the D-Health Trial.

In spite of including more trials, our findings are similar to the previous meta-analyses. This may suggest that it is unlikely that more RCTs will show any significant impact of vitamin D as a cardioprotective intervention.

Our meta-analysis has many strengths. It has very low heterogeneity in all of the outcomes, increased sample size by almost 30%, and increased power of the statistical analysis compared to the previous meta-analyses. Moreover, we registered our meta-analysis on the PROSPERO database and followed a rigorous methodology.

Vitamin D supplementation can cause different adverse effects when taken in doses greater than 4000 IU daily. These include hypercalcemia, hypercalcuria, constipation, confusion, disorientation, and arrhythmias.

Our research also has some limitations. As it is a meta-analysis, we are considering study-level data, not patient-level data. Four RCTs were judged to be at a medium risk of bias. The follow-up periods of the individual RCTs were not very long, which could deter us from detecting some potential beneficial cardiovascular effects. Most of the trials did not have cardiovascular outcomes as a primary outcome. Also, very few trials reported data on heart failure and coronary revascularization, causing their results to be underpowered.

The definition of MACE also varied a lot between different trials. The limited follow-up periods of individual studies may have prevented the detection of potential cardiovascular effects of vitamin D supplementation. The medium risk of bias in some included studies may also impart some bias in our findings.

There are many implications of our meta-analysis. Regarding clinical implications, our meta-analysis supports the existing literature that vitamin D does not confer a benefit to people regarding their cardiovascular health and, thus, should not be used for this purpose. Moreover, our meta-analysis suggests that more RCTs with longer follow-ups are needed to better detect any cardiovascular effects. The RCTs should also be designed through risk factor optimization to include patients with an increased risk of cardiovascular disease.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

After a comprehensive database search yielding 9596 records with five records identified through other sources, we screened the articles, and 18 RCTs were included in our meta-analysis12,13,20,25Not reported39. The PRISMA flow chart is presented in Figure 1. Seven studies included only postmenopausal women, while other studies included older patients, patients on hemodialysis, and patients with heart failure. The follow-up period of the studies ranged from 1 to 6 years. Out of the 18 RCTs, 15 trials used cholecalciferol (vitamin D3), two trials used ergocalciferol31,33, and one trial38 used alfacalcidol as the intervention.

Cumulatively 108 385 participants are included in this meta-analysis, with 54 636 in the vitamin D group and 53 749 in the control group. The mean age was found to be 67.68 years. The study characteristics are presented in Table 1.

Figure 1

PRISMA 2020 flow chart. Flow chart of included and excluded trials. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Characteristics of included studies

Study IDCountryNumber of patientsStudy periodFollow-up period (years)Vitamin D type and dosageAge mean (SD) (vitamin D vs. placebo)Male n (vitamin D vs. placebo)Current smoker no. (vitamin D vs. placebo)BMI, mean (SD) (vitamin D vs. placebo)Total cholesterol, mean (SD), mg/dl (vitamin D vs. placebo)Baseline 25-hydroxyvitamin D level, mean (SD), ng/ml (vitamin D vs. placebo)Statin user, No. (vitamin D vs. placebo)Systolic BP, mmHg, mean (SD) (vitamin D vs. placebo)HTN, no. (vitamin D vs. placebo)DM, no. (vitamin D vs. placebo)
Aloia et al.25 United States27NA2 yVitamin D3 400 IU/d64.1 (1.5) vs. 64.9 (1.7)0 vs. 0NANANA21.9 (7) vs. 26.6 (12)NANANANA
Baron et al.28 United States22594 y3 yVitamin D3 1000 IU /d58.3 (7.0) vs. 58.2 (7.0)358 vs. 35539 vs. 3529.1 (4.6) vs. 29.0 (4.9)NA24.88 (8.09) vs. 24.24 (7.84)NANANANA
Chatterjee et al.36 United States23855 y2.9 yVitamin D3 400 IU/d59.6 (9.8) vs. 60.4 (10.0)663 vs. 66074 vs. 7932 (4.5) vs. 32.1 (4.4)NA27.8 (10.2) vs. 28.2 (10.1)511 vs. 501NANA423 vs. 423
D-Health TrialAustralia213156 y5 yVitamin D3 60000 IU/moNA5765 vs. 5760NANANANA3769 vs. 3681NA4483 vs. 4368NA
EVITA/Zitterman et al.Germany4003 y2.7 yVitamin D3 400 IU/d55.5 (4.0) vs. 54 (3.5)166 vs. 166NA27.9 (2.0) vs. 27.9 (1.6)NA32.2 (6.7) vs. 36.3 (6.8)113 vs. 105115.5 (7.5) vs. 117 (6.9)57 vs. 6351 vs. 46
J-DAVID/Shoji et al.Japan9643 y4 yOral alfacalcidol 0.5 μg/d64.75 (3.7) vs. 64.6 (3.5)301 vs. 277NA21.15 (1.3) vs. 21.1 (1.2)153.2 (12.4) vs. 150 (11.5)NA77 vs. 81145 (8.7) vs. 147.5 (7.5)NA207 vs. 204
Komulainen et al.27 Finland2258 y5 yVitamin D3, 300 IU/d, lowered to 100 IU/d in 5th year52.87 (0.3) vs. 52.6 (0.3)0 vs. 0NA27.1 (0.5) vs. 26.5 (0.5)NA28.1 (2.8) vs. 28.0 (2.5)NANANA2 vs. 3
Ott et al.26 United States86NA2 yVitamin D3, 0.25 μg capsules (2 per day in the start and then increased by 1 or 2 capsules/day later in the study67.9 (1.0) vs. 67.1 (1.2)0 vs. 0NANANA26.7 (1.9) vs. 26.3 (2.4)NANANANA
RECORD/Grant et al.37 United Kingdom52923 y5.2 yVitamin D3, 800 IU/d77 (6) vs. 77 (6)15 vs. 15299 vs. 320NANANANANANANA
Schleithoff et al.30 Germany1231 y1.3 yVitamin D3, 2000 IU/d57.6 (7.5) vs. 53.3 (9)52 vs. 509 vs. 726.3 (3.8) vs. 26 (3.1)NA16.1 (2.9) vs. 16.1 (2.9)53 vs. 42120 (6) vs. 125 (8)38 vs. 3220 vs. 23
STOP IT/Gallagher et al.31 United States489NA3 yCalcitriol 0.5 μg/d72 (3) vs. 71 (4)0 vs. 0NANANA78.0 (21.6) vs. 80.5 (27.4)NANANANA
Trivedi et al.32 United Kingdom26866 y5 yVitamin D3, 100 000 IU/4 mo74.8 (4.6) vs. 74.7 (4.6)1019 vs. 101859 vs. 5324.3 (3.4) vs. 24.4 (3.0)NANANANANANA
VIDA/Scragg et al.13 New Zealand51081 y3.3 yVitamin D3 200000 IU initial bolus dose then 100000 IU(2.5 mg) capsule65.9 (8.3) vs. 65.9 (8.3)1512 vs. 1457164 vs. 15628.4 (5.1) vs. 28.5 (5.1)185 (42) vs. 189 (42)24.4 (9.6) vs. 24.4 (9.6)NA139 (19) vs. 139 (19)34 vs. 40265 vs. 239
Virtanen et al.29 Finland24956 y5 yVitamin D3 1600 IU/d68.2 (4.4) vs. 68.2 (4.5)968 vs. 458593 vs. 29227.0 (4.3) vs. 27.2 (4.3)NANA462 vs. 255NA694 vs. 353154 vs. 68
Vital D/Sanders et al.34 Australia22562 y2.96 yVitamin D3, 500 000 IU/y76.4 (5.7) vs. 76.5 (5)0 vs. 0NANANA53 (7) vs. 47 (5)NANANANA
VITAL/Manson et al.United States258713 y5.3 yVitamin D3 2000 IU/d67.1 (7.0) vs. 67.1 (7.1)6380 vs. 6406921 vs. 91528.1 (5.7) vs. 28.1 (5.8)NANA4822 vs. 4702NA6352 vs. 64391812 vs. 1737
WHI/Jackson et al.39 United States3628210 y7 yVitamin D3, 400 IU/d62.4 (7.0) vs. 62.4 (6.9)0 vs. 01405 vs. 135629.1 (5.9) vs. 29.0 (5.9)208.1 vs. 208.1NA1178 vs. 1149127 (17) vs. 128 (17)5447 vs. 54761055 vs. 1036
Zhu et al.33 Australia1201 y5 yVitamin D2, 1000 IU/d75.4 (2.7) vs. 74.4 (2.4)0 vs. 0NA27.6 (4) vs. 28.2 (4.1)NA26.8 (10.4) vs. 28 (10.4)NANANANA

Incidence of MACE

A total of 10 RCTs reported the incidence of major adverse cardiovascular events (MACE). According to our pooled data, the vitamin D intervention was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events, with the risk ratio being 0.99 (95% CI: 0.94 to 1.03). The heterogeneity between studies was found to be low (I 2=8%) for this outcome (Fig. 2).

Figure 2

Comparison of incidence of MACE between patients receiving vitamin D or control. IV, inverse variance. MACE, major adverse cardiovascular events.

Figure image at the original source: open the original paper. This file is not included in this text import.

All-cause mortality

The all-cause mortality was reported by 15 RCTs in our meta-analysis. We found no difference in the all-cause mortality between the two groups in our meta-analysis [RR 0.96; 95% CI: 0.92 to 1.00]. The heterogeneity between studies was found to be low (I 2=0%) (Fig. 3).

Figure 3

Comparison of all-cause mortality between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.

Cardiovascular death

A total of 10 RCTs reported the outcome of cardiovascular death. Vitamin D intervention was not associated with a statistically significant decrease in cardiovascular death [RR 0.99; 95% CI: 0.91 to 1.07]. The heterogeneity between studies was found to be low (I 2=0%) for this outcome (Fig. 4).

Figure 4

Comparison of incidence of cardiovascular death between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.

Incidence of MI

The incidence of MI was reported by 14 RCTs in our meta-analysis. We found no difference in the incidence of MI between the two groups in our meta-analysis [RR 0.97; 95% CI: 0.90 to 1.04]. The heterogeneity between studies was found to be low (I 2=0%) (Supplementary Fig. S1.1, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of cerebrovascular accident

According to our meta-analysis of 12 studies reporting this outcome, vitamin D did not reduce the incidence of cerebrovascular accidents [RR 1.04; 95% CI: 0.97 to 1.12; I 2=0%] (Supplementary Fig. S1.2, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of heart failure

Only two studies reported this outcome, and the meta-analysis of these two studies showed no statistically significant difference between vitamin D and control groups [RR 1.17; 95% CI: 0.86 to 1.60; I 2=0%] (Supplementary Fig. S1.3, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of coronary revascularization

Only three studies reported this outcome and the meta-analysis of these three studies showed no statistically significant difference between vitamin D and control groups [RR 0.91; 95% CI: 0.80 to 1.03; I 2=0%] (Supplementary Fig. S1.4, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Risk of bias of included studies

After assessing each study for the risk of bias using the Rob 2.0 tool, 14 out of 18 studies were judged to be at low risk of bias. Four studies were judged to be at medium risk of bias due to concerns related to attrition bias, allocation concealment, and prespecified statistical plan.

The complete risk of bias assessment is presented in Supplementary Figure S1.5. (Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusion

According to our meta-analysis, vitamin D supplementation did not reduce major adverse cardiovascular events, other cardiovascular parameters, and all-cause mortality. Therefore, vitamin D should not be recommended for the prevention of cardiovascular disease.

Source: Conclusion
Authors’ abstract

Objective:

To evaluate the effect of vitamin D supplementation on cardiovascular outcomes.

Methods:

After searching different databases, we retrieved and included randomized controlled trials on long-term supplementation of vitamin D (≥1-year intervention) and reporting cardiovascular outcomes. We calculated risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes.

Results:

Compared to the control group, the vitamin D group was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events (MACE) [risk ratio=0.99; 95% CI: 0.94 to 1.03]. We found no difference between the vitamin D group and the control group for the outcomes of incidences of myocardial infarction, heart failure, coronary revascularization, cardiovascular death, and all-cause mortality. The heterogeneity was low for all outcomes.

Conclusion:

According to our meta-analysis, vitamin D supplementation did not reduce major adverse cardiovascular events, other cardiovascular parameters, and all-cause mortality.

Read the full paper

Introduction

Highlights

  • Compared to the control group, the vitamin D group was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events (MACE).

  • We found no difference between the vitamin D group and the control group for the outcomes of incidences of myocardial infarction, heart failure, coronary revascularization, cardiovascular death, and all-cause mortality.

Vitamin D deficiency (VDD) is prevalent worldwide, with 15.7% of individuals having serum 25-hydroxyvitamin D levels below 30 nmol/l1. Cardiovascular disease (CVD) is a significant public health issue and the primary contributor to mortality globally, with around 17.7 million deaths attributed to CVD2. CVD development is influenced by a multitude of factors. Among the most significant contributors to CVD is the nutritional component3.

VDD and cardiovascular ailments have become quite prevalent, with both conditions commonly occurring together4. Numerous observational studies5,6 have shown a correlation between vitamin D deficiency and an elevated risk of cardiovascular disease and overall mortality. In the same manner, multiple studies have examined the correlation between vitamin D deficiency and coronary artery diseases (CADs)7Not reported9. Approximately 95% of patients admitted with acute coronary syndrome (ACS) in a cohort study exhibited low vitamin D levels10.

Similarly, Dziedzic et al. 11 conducted a study that revealed that patients with a history of myocardial infarction had low levels of vitamin D.

However, many randomized clinical trials have not been able to establish any conclusive connection between vitamin D supplementation and a decrease in cardiovascular outcomes like major adverse cardiovascular events12,13. It should be noted that these trials were carried out on diverse subject groups without taking into account their baseline levels of 25(OH)D concentration14.

A total of five meta-analyses have been published to assess the impact of vitamin D supplementation on cardiovascular mortality15Not reported19. Three meta-analyses15Not reported17 included trials that administered both vitamin D and calcium together, making it difficult to determine the individual effect of vitamin D. All of the meta-analyses have reported that there is no cardiovascular benefit of vitamin D supplementation. Hence, the US Preventive Services Task Force has not recommended the administration of vitamin D to prevent cardiovascular disease.

Our meta-analysis is an updated analysis because it includes a recently published large-scale RCT with 21 315 participants20. Thus, we carried out an updated meta-analysis of RCTs that evaluate the efficacy of vitamin D supplementation for preventing cardiovascular disease.

Materials and methods

Our meta-analysis was conducted according to the guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions and followed the reporting guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA, Supplemental Digital Content 1, http://links.lww.com/MS9/A581) statement21,22. Our study did not require any ethical approval. This meta-analysis has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). This review has been reported in line with the AMSTAR criteria (Supplemental Digital Content 2, http://links.lww.com/MS9/A582).

Eligibility criteria

The inclusion criteria were as follows: (1) only RCTs; (2) adults who received vitamin D in various forms and doses, with or without concurrent calcium administration; (3) studies with at least one cardiovascular outcome reported; (4) studies on only long-term supplementation (≥1-year intervention) of vitamin D. Studies that did not include cardiovascular outcomes or with an intervention period <1 year were excluded. We also excluded observational studies and review studies.

Information sources

We searched electronic databases, gray literature sources, and international trial registries from their inception until September 1, 2023, without imposing any language restrictions. The databases and registries searched included the Cochrane Central Register of Controlled Trials (accessed via the Cochrane Library), MEDLINE (via PubMed), Embase (via Ovid), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform portal. The reference lists of the included studies and relevant meta-analyses were also screened to find other RCTs. A search strategy consisting of a combination of keywords and MeSH terms like vitamin D, ergocalciferol, cholecalciferol, cardiac, myocardial, and cardiovascular were used.

Study selection and data extraction

The retrieved articles from the search were imported into Mendeley Desktop 1.19.8, and any duplicate articles were removed. Two review authors then conducted a two-step process to screen studies: first, by assessing titles and abstracts, and secondly, by reviewing the full-text versions of selected studies. Any disagreements during this process were resolved through discussion, with a plan in place for a third review author to serve as an arbitrator if needed. A PRISMA flow chart was used to visually present the selection process.

Following the completion of the study selection, two reviewers extracted relevant data from selected studies using a standardized data extraction form. This information encompassed various aspects, including study details (such as design, location, year of publication, and author), participant characteristics (including number of participants, age range, and gender distribution), intervention specifics (dosage, duration, and follow-up period), baseline parameters, comparator, and outcome measures assessed.

Outcome measures

The primary outcome is the incidence of major adverse cardiovascular events (MACE). The secondary outcomes included: (1) all-cause mortality, (2) incidence of cardiovascular death, (3) incidence of MI, (4) incidence of cerebrovascular events, (5) incidence of HF, and (6) incidence of coronary revascularization.

Risk of bias assessment

We assessed the risk of bias in the included studies using the revised Cochrane “Risk of bias” tool for randomized trials (RoB 2.0), which assesses bias in five domains: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in the measurement of the outcome, and (5) bias in the selection of the reported result23. Two authors independently assessed the risk of bias in each study that was included, categorizing it as either low-risk, high-risk or have some concerns.

In cases where there were discrepancies between the assessments of the two original authors, a third reviewer was consulted to help make a final decision.

Data synthesis

For each trial, we reported dichotomous outcomes as relative risk (RR) along with 95% confidence intervals. The meta-analysis was conducted when at least two studies reported the relevant outcome data. We used the DerSimonian and Laird random-effects model in our meta-analyses. For detection and quantification of heterogeneity, we calculated the χ 2 test and I 2 statistic. We interpreted I 2 values according to the Cochrane Handbook for Systematic Reviews of Interventions section 10.10. P value <0.10 was considered statistically significant for the χ 2 test24.

All statistical analyses were performed using Review Manager (RevMan, Version 5.4; The Cochrane Collection, Copenhagen, Denmark). The study characteristics and findings of the included studies were presented in the form of tables.

Results

After a comprehensive database search yielding 9596 records with five records identified through other sources, we screened the articles, and 18 RCTs were included in our meta-analysis12,13,20,25Not reported39. The PRISMA flow chart is presented in Figure 1. Seven studies included only postmenopausal women, while other studies included older patients, patients on hemodialysis, and patients with heart failure. The follow-up period of the studies ranged from 1 to 6 years. Out of the 18 RCTs, 15 trials used cholecalciferol (vitamin D3), two trials used ergocalciferol31,33, and one trial38 used alfacalcidol as the intervention.

Cumulatively 108 385 participants are included in this meta-analysis, with 54 636 in the vitamin D group and 53 749 in the control group. The mean age was found to be 67.68 years. The study characteristics are presented in Table 1.

Figure 1

PRISMA 2020 flow chart. Flow chart of included and excluded trials. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Characteristics of included studies

Study IDCountryNumber of patientsStudy periodFollow-up period (years)Vitamin D type and dosageAge mean (SD) (vitamin D vs. placebo)Male n (vitamin D vs. placebo)Current smoker no. (vitamin D vs. placebo)BMI, mean (SD) (vitamin D vs. placebo)Total cholesterol, mean (SD), mg/dl (vitamin D vs. placebo)Baseline 25-hydroxyvitamin D level, mean (SD), ng/ml (vitamin D vs. placebo)Statin user, No. (vitamin D vs. placebo)Systolic BP, mmHg, mean (SD) (vitamin D vs. placebo)HTN, no. (vitamin D vs. placebo)DM, no. (vitamin D vs. placebo)
Aloia et al.25 United States27NA2 yVitamin D3 400 IU/d64.1 (1.5) vs. 64.9 (1.7)0 vs. 0NANANA21.9 (7) vs. 26.6 (12)NANANANA
Baron et al.28 United States22594 y3 yVitamin D3 1000 IU /d58.3 (7.0) vs. 58.2 (7.0)358 vs. 35539 vs. 3529.1 (4.6) vs. 29.0 (4.9)NA24.88 (8.09) vs. 24.24 (7.84)NANANANA
Chatterjee et al.36 United States23855 y2.9 yVitamin D3 400 IU/d59.6 (9.8) vs. 60.4 (10.0)663 vs. 66074 vs. 7932 (4.5) vs. 32.1 (4.4)NA27.8 (10.2) vs. 28.2 (10.1)511 vs. 501NANA423 vs. 423
D-Health TrialAustralia213156 y5 yVitamin D3 60000 IU/moNA5765 vs. 5760NANANANA3769 vs. 3681NA4483 vs. 4368NA
EVITA/Zitterman et al.Germany4003 y2.7 yVitamin D3 400 IU/d55.5 (4.0) vs. 54 (3.5)166 vs. 166NA27.9 (2.0) vs. 27.9 (1.6)NA32.2 (6.7) vs. 36.3 (6.8)113 vs. 105115.5 (7.5) vs. 117 (6.9)57 vs. 6351 vs. 46
J-DAVID/Shoji et al.Japan9643 y4 yOral alfacalcidol 0.5 μg/d64.75 (3.7) vs. 64.6 (3.5)301 vs. 277NA21.15 (1.3) vs. 21.1 (1.2)153.2 (12.4) vs. 150 (11.5)NA77 vs. 81145 (8.7) vs. 147.5 (7.5)NA207 vs. 204
Komulainen et al.27 Finland2258 y5 yVitamin D3, 300 IU/d, lowered to 100 IU/d in 5th year52.87 (0.3) vs. 52.6 (0.3)0 vs. 0NA27.1 (0.5) vs. 26.5 (0.5)NA28.1 (2.8) vs. 28.0 (2.5)NANANA2 vs. 3
Ott et al.26 United States86NA2 yVitamin D3, 0.25 μg capsules (2 per day in the start and then increased by 1 or 2 capsules/day later in the study67.9 (1.0) vs. 67.1 (1.2)0 vs. 0NANANA26.7 (1.9) vs. 26.3 (2.4)NANANANA
RECORD/Grant et al.37 United Kingdom52923 y5.2 yVitamin D3, 800 IU/d77 (6) vs. 77 (6)15 vs. 15299 vs. 320NANANANANANANA
Schleithoff et al.30 Germany1231 y1.3 yVitamin D3, 2000 IU/d57.6 (7.5) vs. 53.3 (9)52 vs. 509 vs. 726.3 (3.8) vs. 26 (3.1)NA16.1 (2.9) vs. 16.1 (2.9)53 vs. 42120 (6) vs. 125 (8)38 vs. 3220 vs. 23
STOP IT/Gallagher et al.31 United States489NA3 yCalcitriol 0.5 μg/d72 (3) vs. 71 (4)0 vs. 0NANANA78.0 (21.6) vs. 80.5 (27.4)NANANANA
Trivedi et al.32 United Kingdom26866 y5 yVitamin D3, 100 000 IU/4 mo74.8 (4.6) vs. 74.7 (4.6)1019 vs. 101859 vs. 5324.3 (3.4) vs. 24.4 (3.0)NANANANANANA
VIDA/Scragg et al.13 New Zealand51081 y3.3 yVitamin D3 200000 IU initial bolus dose then 100000 IU(2.5 mg) capsule65.9 (8.3) vs. 65.9 (8.3)1512 vs. 1457164 vs. 15628.4 (5.1) vs. 28.5 (5.1)185 (42) vs. 189 (42)24.4 (9.6) vs. 24.4 (9.6)NA139 (19) vs. 139 (19)34 vs. 40265 vs. 239
Virtanen et al.29 Finland24956 y5 yVitamin D3 1600 IU/d68.2 (4.4) vs. 68.2 (4.5)968 vs. 458593 vs. 29227.0 (4.3) vs. 27.2 (4.3)NANA462 vs. 255NA694 vs. 353154 vs. 68
Vital D/Sanders et al.34 Australia22562 y2.96 yVitamin D3, 500 000 IU/y76.4 (5.7) vs. 76.5 (5)0 vs. 0NANANA53 (7) vs. 47 (5)NANANANA
VITAL/Manson et al.United States258713 y5.3 yVitamin D3 2000 IU/d67.1 (7.0) vs. 67.1 (7.1)6380 vs. 6406921 vs. 91528.1 (5.7) vs. 28.1 (5.8)NANA4822 vs. 4702NA6352 vs. 64391812 vs. 1737
WHI/Jackson et al.39 United States3628210 y7 yVitamin D3, 400 IU/d62.4 (7.0) vs. 62.4 (6.9)0 vs. 01405 vs. 135629.1 (5.9) vs. 29.0 (5.9)208.1 vs. 208.1NA1178 vs. 1149127 (17) vs. 128 (17)5447 vs. 54761055 vs. 1036
Zhu et al.33 Australia1201 y5 yVitamin D2, 1000 IU/d75.4 (2.7) vs. 74.4 (2.4)0 vs. 0NA27.6 (4) vs. 28.2 (4.1)NA26.8 (10.4) vs. 28 (10.4)NANANANA

Incidence of MACE

A total of 10 RCTs reported the incidence of major adverse cardiovascular events (MACE). According to our pooled data, the vitamin D intervention was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events, with the risk ratio being 0.99 (95% CI: 0.94 to 1.03). The heterogeneity between studies was found to be low (I 2=8%) for this outcome (Fig. 2).

Figure 2

Comparison of incidence of MACE between patients receiving vitamin D or control. IV, inverse variance. MACE, major adverse cardiovascular events.

Figure image at the original source: open the original paper. This file is not included in this text import.

All-cause mortality

The all-cause mortality was reported by 15 RCTs in our meta-analysis. We found no difference in the all-cause mortality between the two groups in our meta-analysis [RR 0.96; 95% CI: 0.92 to 1.00]. The heterogeneity between studies was found to be low (I 2=0%) (Fig. 3).

Figure 3

Comparison of all-cause mortality between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.

Cardiovascular death

A total of 10 RCTs reported the outcome of cardiovascular death. Vitamin D intervention was not associated with a statistically significant decrease in cardiovascular death [RR 0.99; 95% CI: 0.91 to 1.07]. The heterogeneity between studies was found to be low (I 2=0%) for this outcome (Fig. 4).

Figure 4

Comparison of incidence of cardiovascular death between patients receiving vitamin D or control. IV, inverse variance.

Figure image at the original source: open the original paper. This file is not included in this text import.

Incidence of MI

The incidence of MI was reported by 14 RCTs in our meta-analysis. We found no difference in the incidence of MI between the two groups in our meta-analysis [RR 0.97; 95% CI: 0.90 to 1.04]. The heterogeneity between studies was found to be low (I 2=0%) (Supplementary Fig. S1.1, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of cerebrovascular accident

According to our meta-analysis of 12 studies reporting this outcome, vitamin D did not reduce the incidence of cerebrovascular accidents [RR 1.04; 95% CI: 0.97 to 1.12; I 2=0%] (Supplementary Fig. S1.2, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of heart failure

Only two studies reported this outcome, and the meta-analysis of these two studies showed no statistically significant difference between vitamin D and control groups [RR 1.17; 95% CI: 0.86 to 1.60; I 2=0%] (Supplementary Fig. S1.3, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Incidence of coronary revascularization

Only three studies reported this outcome and the meta-analysis of these three studies showed no statistically significant difference between vitamin D and control groups [RR 0.91; 95% CI: 0.80 to 1.03; I 2=0%] (Supplementary Fig. S1.4, Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Risk of bias of included studies

After assessing each study for the risk of bias using the Rob 2.0 tool, 14 out of 18 studies were judged to be at low risk of bias. Four studies were judged to be at medium risk of bias due to concerns related to attrition bias, allocation concealment, and prespecified statistical plan.

The complete risk of bias assessment is presented in Supplementary Figure S1.5. (Supplemental Digital Content 3, http://links.lww.com/MS9/A583).

Discussion

According to our meta-analysis of 18 RCTs on 108 385 patients, vitamin D was not associated with a statistically significant decrease in the incidence of major adverse cardiovascular events (MACE), all-cause mortality, cardiovascular death, incidence of heart failure, myocardial infarction, cerebrovascular accident, and coronary revascularization. It is noteworthy to note that the evidence was not sufficient on the outcomes of cerebrovascular accident and coronary revascularization rates. Some previous observational studies5,6 showed a potential effect in reducing adverse cardiovascular events but no such association has been observed in many RCTs and previous meta-analyses18,19 conducted on vitamin D effect on cardiovascular outcomes.

Our meta-analysis includes data from a very large randomized controlled trial, the D-Health trial20, which was not included in the previous meta-analyses.

Our meta-analysis’ findings are similar to the results of the previous meta-analyses. Barbarawi et al. 18 reported that vitamin D did not significantly reduce major adverse cardiovascular events [RR 1.00; 95% CI: 0.95 to 1.06]. The effect on myocardial infarction, stroke, CVD mortality, and all-cause mortality was also insignificant. Pei et al. 19 conducted a meta-analysis on 18 RCTs, and they showed a similar effect on all cardiovascular outcomes, including MACE, myocardial infarction, heart failure, and cerebrovascular events. Our meta-analysis is different from the previous meta-analyses in two ways: (1) in this study, we have only included RCTs on long-term (≥1-year intervention) vitamin D supplementation; (2) inclusion of a large trial, the D-Health Trial.

In spite of including more trials, our findings are similar to the previous meta-analyses. This may suggest that it is unlikely that more RCTs will show any significant impact of vitamin D as a cardioprotective intervention.

Our meta-analysis has many strengths. It has very low heterogeneity in all of the outcomes, increased sample size by almost 30%, and increased power of the statistical analysis compared to the previous meta-analyses. Moreover, we registered our meta-analysis on the PROSPERO database and followed a rigorous methodology.

Vitamin D supplementation can cause different adverse effects when taken in doses greater than 4000 IU daily. These include hypercalcemia, hypercalcuria, constipation, confusion, disorientation, and arrhythmias.

Our research also has some limitations. As it is a meta-analysis, we are considering study-level data, not patient-level data. Four RCTs were judged to be at a medium risk of bias. The follow-up periods of the individual RCTs were not very long, which could deter us from detecting some potential beneficial cardiovascular effects. Most of the trials did not have cardiovascular outcomes as a primary outcome. Also, very few trials reported data on heart failure and coronary revascularization, causing their results to be underpowered.

The definition of MACE also varied a lot between different trials. The limited follow-up periods of individual studies may have prevented the detection of potential cardiovascular effects of vitamin D supplementation. The medium risk of bias in some included studies may also impart some bias in our findings.

There are many implications of our meta-analysis. Regarding clinical implications, our meta-analysis supports the existing literature that vitamin D does not confer a benefit to people regarding their cardiovascular health and, thus, should not be used for this purpose. Moreover, our meta-analysis suggests that more RCTs with longer follow-ups are needed to better detect any cardiovascular effects. The RCTs should also be designed through risk factor optimization to include patients with an increased risk of cardiovascular disease.

Conclusion

According to our meta-analysis, vitamin D supplementation did not reduce major adverse cardiovascular events, other cardiovascular parameters, and all-cause mortality. Therefore, vitamin D should not be recommended for the prevention of cardiovascular disease.

Ethical approval

No ethical approval was required for this study.

Consent

No consent was required for this study.

Source of funding

No financial support was received for this study.

Author contribution

M.A., A.M.W.M., N.E.A., and M.F.M.: study conception and design; A.M.W.M., N.E.A., M.F.M., and T.B.: study conduct and acquisition of data; A.M.W.M., N.E.A., M.F.M., S.V.U., and A.A.: data analysis; M.A., N.E.A., M.F.M., T.B., S.L., and I.W.F.: data interpretation; A.M.W.M., N.E.A., M.A., M.F.M., T.B., and S.V.U.: drafting of the manuscript; M.A., I.W.F., S.L., H.F., A.A., R.M., and M.K.: critical revision of the manuscript. Final approval of the version was approved by all the authors to be published. All authors agree to be accountable for all aspects of the work.

Conflicts of interest disclosure

The authors declare no conflicts of interest.

Research registration unique identifying number (UIN)

PROSPERO registration number: CRD42023458654.

Guarantor

Kamal Kandel.

Data availability statement

The data that support the findings of this study are available from the corresponding author, K.K., upon reasonable request.

Provenance and peer review

Not applicable.

Supplementary Material

Supplement file at the original source: open the original paper. This file is not included in this text import.
Figure image at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Figure image at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Figure image at the original source: open the original paper. This file is not included in this text import.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, www.lww.com/annals-of-medicine-and-surgery.

Published online 14 August 2024

References

1 Cui A Zhang T Xiao P . Global and regional prevalence of vitamin D deficiency in population-based studies from 2000 to 2022: A pooled analysis of 7.9 million participants . Front Nutr 2023 ;10 :1070808 . 37006940 10.3389/fnut.2023.1070808 PMC10064807
2 Zittermann A . Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003 ;89 :552Not reported572 . 12720576 10.1079/BJN2003837
3 Holick MF . Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis . Am J Clin Nutr 2004 ;79 :362Not reported371 . 14985208 10.1093/ajcn/79.3.362
4 Kienreich K Tomaschitz A Verheyen N . Vitamin D and cardiovascular disease . Nutrients 2013 ;5 :3005Not reported3021 . 23912328 10.3390/nu5083005 PMC3775239
5 Giovannucci E Liu Y Hollis BW . 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study . Arch Intern Med 2008 ;168 :1174Not reported1180 . 18541825 10.1001/archinte.168.11.1174 PMC3719391
6 Pekkanen MP Ukkola O Hedberg P . Serum 25-hydroxyvitamin D is associated with major cardiovascular risk factors and cardiac structure and function in patients with coronary artery disease . Nutr Metab Cardiovasc Dis 2015 ;25 :471Not reported478 . 25816731 10.1016/j.numecd.2015.02.005
7 Milazzo V De Metrio M Cosentino N . Vitamin D and acute myocardial infarction . World J Cardiol 2017 ;9 :14Not reported20 . 28163832 10.4330/wjc.v9.i1.14 PMC5253190
8 Anderson JL May HT Horne BD . Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population . Am J Cardiol 2010 ;106 :963Not reported968 . 20854958 10.1016/j.amjcard.2010.05.027
9 Aleksova A Belfiore R Carriere C . Vitamin D deficiency in patients with acute myocardial infarction: an Italian single-center study . Int J Vitam Nutr Res 2015 ;85 :23Not reported30 . 26780274 10.1024/0300-9831/a000220
10 Lee JH Gadi R Spertus JA . Prevalence of vitamin D deficiency in patients with acute myocardial infarction . Am J Cardiol 2011 ;107 :1636Not reported1638 . 21439530 10.1016/j.amjcard.2011.01.048 PMC4320644
11 Dziedzic EA Gąsior JS Pawłowski M . Association of vitamin D deficiency and degree of coronary artery disease in cardiac patients with type 2 diabetes . J Diab Res 2017 ;2017 :3929075 . 10.1155/2017/3929075 PMC5688254 29230421
12 Zittermann A Ernst JB Prokop S . Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily . Eur Heart J 2017 ;38 :2279Not reported2286 . 28498942 10.1093/eurheartj/ehx235
13 Scragg R Stewart AW Waayer D . Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: a randomized clinical trial . JAMA Cardiol 2017 ;2 :608Not reported616 . 28384800 10.1001/jamacardio.2017.0175 PMC5815022
14 Sofianopoulou E Kaptoge SK Afzal S . Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses . Lancet Diab Endocrinol 2021 ;9 :837Not reported846 . 10.1016/S2213-8587(21)00263-1 PMC8600124 34717822
15 Bjelakovic G Gluud LL Nikolova D . Vitamin D supplementation for prevention of mortality in adults . Cochrane Database Syst Rev 2014 ;2014 :CD007470 . 24414552 10.1002/14651858.CD007470.pub3 PMC11285307
16 Bolland MJ Grey A Gamble GD . The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis . Lancet Diab Endocrinol 2014 ;2 :307Not reported320 . 10.1016/S2213-8587(13)70212-2 24703049
17 Ford JA MacLennan GS Avenell A . RECORD Trial Group, cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis . Am J Clin Nutr 2014 ;100 :746Not reported755 . 25057156 10.3945/ajcn.113.082602
18 Barbarawi M Kheiri B Zayed Y . Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis . JAMA Cardiol 2019 ;4 :765Not reported776 . 31215980 10.1001/jamacardio.2019.1870 PMC6584896
19 Pei Y-Y Zhang Y Peng X-C . Association of vitamin D supplementation with cardiovascular events: a systematic review and meta-analysis . Nutrients 2022 ;14 :3158 . 35956336 10.3390/nu14153158 PMC9370368
20 Thompson B Waterhouse M English DR . Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial . BMJ 2023 ;381 :e075230 . 37380191 10.1136/bmj-2023-075230 PMC10302209
21 Higgins JPT Thomas J Chandler J . (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 6.4 (updated August 2023), n.d. Accessed 13 September 2023. https://training.cochrane.org/handbook
22 Page MJ McKenzie JE Bossuyt PM . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews . Syst Rev 2021 ;10 :89 . 33781348 10.1186/s13643-021-01626-4 PMC8008539
23 Sterne JAC Savović J Page MJ . RoB 2: a revised tool for assessing risk of bias in randomised trials . BMJ 2019 ;366 :l4898 . 31462531 10.1136/bmj.l4898
24 Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training (n.d.). Accessed 1 October 2022. https://training.cochrane.org/handbook
25 Aloia JF Vaswani A Yeh JK . Calcitriol in the treatment of postmenopausal osteoporosis . Am J Med 1988 ;84 :401Not reported408 . 3279769 10.1016/0002-9343(88)90259-8
26 Ott SM Chesnut CH . Calcitriol treatment is not effective in postmenopausal osteoporosis . Ann Intern Med 1989 ;110 :267Not reported274 . 2913914 10.7326/0003-4819-110-4-267
27 Komulainen M Kröger H Tuppurainen MT . Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial . J Clin Endocrinol Metab 1999 ;84 :546Not reported552 . 10022414 10.1210/jcem.84.2.5496
28 Baron JA Barry EL Mott LA . A trial of calcium and vitamin D for the prevention of colorectal adenomas . N Engl J Med 2015 ;373 :1519Not reported1530 . 26465985 10.1056/NEJMoa1500409 PMC4643064
29 Virtanen JK Nurmi T Aro A . Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial . Am J Clin Nutr 2022 ;115 :1300Not reported1310 . 34982819 10.1093/ajcn/nqab419 PMC9071497
30 Schleithoff SS Zittermann A Tenderich G . Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial2 . Am J Clin Nutr 2006 ;83 :754Not reported759 . 16600924 10.1093/ajcn/83.4.754
31 Gallagher JC Fowler SE Detter JR . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss . J Clin Endocrinol Metab 2001 ;86 :3618Not reported3628 . 11502787 10.1210/jcem.86.8.7703
32 Trivedi DP Doll R Khaw KT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial . BMJ 2003 ;326 :469 . 12609940 10.1136/bmj.326.7387.469 PMC150177
33 Zhu K Devine A Dick IM . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial . J Clin Endocrinol Metab 2008 ;93 :743Not reported749 . 18089701 10.1210/jc.2007-1466
34 Sanders KM Stuart AL Williamson EJ . Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial . JAMA 2010 ;303 :1815Not reported1822 . 20460620 10.1001/jama.2010.594
35 Manson JE Cook NR Lee I-M . VITAL Research group, vitamin d supplements and prevention of cancer and cardiovascular disease . N Engl J Med 2019 ;380 :33Not reported44 . 30415629 10.1056/NEJMoa1809944 PMC6425757
36 Chatterjee R Fuss P Vickery EM . D2d Research Group, vitamin D supplementation for prevention of cancer: the D2d cancer outcomes (D2dCA) ancillary study . J Clin Endocrinol Metab 2021 ;106 :2767Not reported2778 . 33693713 10.1210/clinem/dgab153 PMC8372641
37 Grant AM Avenell A Campbell MK . Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial . Lancet 2005 ;365 :1621Not reported1628 . 15885294 10.1016/S0140-6736(05)63013-9
38 Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial | Nephrology | JAMA | JAMA Network, (n.d.). Accessed 16 September 2023. https://jamanetwork.com/journals/jama/fullarticle/2718066?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamacardio.2019.1870
39 Jackson RD LaCroix AZ Gass M . Calcium plus vitamin D supplementation and the risk of fractures . New Engl J Med 2006 ;354 :669Not reported683 . 16481635 10.1056/NEJMoa055218
Publication and source details

Original title: Effect of vitamin D supplementation on cardiovascular outcomes: an updated meta-analysis of RCTs

Agha M.W. Mirza; Naiela E. Almansouri; Muhammad F. Muslim; Thahaseen Basheer; Sree V. Uppalapati; Swati Lakra; Hareem Fatima; Arshiya Adhnon; Ivo W. Filho; Ruqeyya Mahmood; Mahendra Kumar; Kamal Kandel; Muhammad Ayyan

Annals of Medicine and Surgery · 2024

* Corresponding authors. Address: Department of Medicine, Mayo Hospital, Nila Gumbad Chowk, Neela Gumbad Lahore, Punjab 54000, Pakistan. Tel.: +92 3238 478 847. E-mail: iamayyan77@gmail.com (M. Ayyan); Department of Medicine, Kathmandu University, Kathmandu, Nepal. Tel.: +977 985 762 5613. E-mail: Kamalkandel010@gmail.com (K. Kandel).Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.2024https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:22:32.245016+00:00

DOI: 10.1097/ms9.0000000000002458 · PMC11543226